M. McGarvey

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.

D. Torigian, M. Soulen, B. Levine, 2018, Gastroenterology.

Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers

M. Morgan, D. Porter, B. Levine, 2015 .

Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer.

D. Torigian, B. Levine, C. June, 2015 .

Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.

D. Torigian, M. Soulen, B. Levine, 2019, Molecular therapy : the journal of the American Society of Gene Therapy.